Faced with a dilemma, the FDA rejects Cempra's antibiotic, demands big safety study
Cempra delivered the FDA’s decision on its antibiotic solithromycin on Thursday morning, a day late and about $185 million short.
Caught on the horns of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
